Product Lifecycle Management, 2006

Executive Summary

The global pharmaceutical market with sales of approximately $550 billion is about to enter a pivotal period in its history. The industry has been used to double digit growth rates but growth has now dropped to below 10% for the first time. In addition to this whole swathes of lucrative high revenue earning drugs are going to lose patent. Ordinarily, the industry would have been able to cope with this after all patent loss is a normal part of the industrial process. But this time the industry faces serious problems, pipelines are notoriously thin. The industry is going to have huge difficulties in replacing those drugs going off patent and the high levels of revenue that they earn. The industry is going to have incorporate the new culture of Product Lifecycle Management (PLM) if it is to salvage some of those lost revenues.
Visiongain’s s new report Product Lifecycle Management, 2006 offers an in depth view of this new work strategy. PLM may not be able to save the industry but in times of low growth, patent loss, generic competition and a dearth of new high earning products it is a one of the few viable options. Visiongain’s Product Lifecycle Management, 2006 explains this new method of business and assesses each major aspect of PLM and how they may improve industrial performance. Visiongain’s Product Lifecycle Management, 2006 has to be an essential part of any pharmaceutical company’s outlook.

Why you should buy this report:

• The level of imminent patent loss is unprecedented in the history of the pharmaceutical industry
• Generic companies can expect at least a 50% share of the patent expired market
• Key product lifecycle management strategies are examined, recent examples considered and the advantages and disadvantages of each assessed
• Leading drugs in the principal R&D based company pipelines are assessed
• The key aspects of the patent system are outlined
• This report considers the latest financial and anecdotal information to enable the most appropriate choice of product lifecycle management strategy to be assessed.